EXHIBIT 99.1


Genus Sells High Energy Implant Product Line; New Company Direction Focuses on
Thin Films Market

     Business Editors

     SUNNYVALE, Calif. -- (BUSINESS WIRE) -- April 16, 1998 -- Genus, Inc. (OTC,
NASDAQ:GGNS) announced today that it has reached an agreement with Varian
Associates to sell selected assets related to its high energy (MeV) ion
implantation equipment product line for approximately $25 million plus
additional payments if certain revenue targets are achieved.  The completion of
this transaction, which includes the transfer of a leased manufacturing facility
in Newburyport, Massachusetts, is subject to standard governmental reviews as
well as approval by Genus shareholders.

     "Our company strategy during the last 18 months has been to strengthen
Genus from both a financial and customer satisfaction standpoint," said James T.
Healy, Genus' president and CEO.  "The sale of our ion implant product
technology to Varian provides us with the resources to better serve the
long-term requirements of our thin film customers."

     Genus' chairman, Dr. William W.R. Elder, commented, "We believe this change
in our business strategy and technology roadmap will help Genus remain a world
class semiconductor equipment supplier as we grow to serve new emerging markets
with our thin film products.  Historically, our CVD technology has been focused
primarily on the tungsten silicide market.  Our tungsten nitride and other film
offerings position Genus to capture additional segments of the deposition
market."

     Founded in 1982, Genus, Inc. designs, manufactures, and markets equipment
used in the fabrication of advanced semiconductor devices.  The Company's
customers include semiconductor manufacturers located throughout the United
States, Europe and the Pacific Rim, including Japan, Korea and Taiwan.  Genus'
corporate offices are located at 1139 Karlstad Drive, Sunnyvale, CA 94089;
telephone (408) 747-7120; fax (408) 747-7199; e-mail PR@genus.com; Internet
http://www.genus.com.

     "Safe Harbor" statement under the Private Securities Litigation Reform Act
of 1995:  Except for historical information, this release contains forward
looking statements dependent on a number of risks and uncertainties, including,
but not limited to, retrenchment in the semiconductor industry, general
conditions in the Company's industry sector, and the additional risks and
uncertainties detailed under "Management's Discussion and Analysis of Results of
Operations and Financial Condition" contained in the Company's annual report on
Form 10-K for the fiscal year ended December 31, 1997.  The Company assumes no
obligation to update the information detailed in this release.

     Note to Editors:  This new release is available through BW NewsOnDemand
Plus by calling 1-888-BUY-GGNS.



     CONTACT:  Genus, Inc.
               Mary F. Bobel, 408/747-7120
               or
               Mathews & Clark
               Bob Climo, 408/736-1120













                                         -2-